Head & Neck Trials
A list of our early phase head and neck trials which are open to recruitment at University College London Hospitals
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Head & Neck cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
OrigAMI-4A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | |
|---|---|
| IRAS Number: | 1009340 |
| Principal Investigator: | Prof Martin Forster |
| Drug Class/ Treatment: | Amivantamab (EGF Receptor and MET Receptor-directed antibody) Monotherapy and combination with SOC |
| Patient Population: | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
Principal Investigator(s):
Dr. martin forster
Associate Professor & Consultant Medical Oncologist
UCL ECMC Clinical Lead
